Investor Presentation First Nine Months of 2023
42
Investor presentation
First nine months of 2023
Novo Nordisk has a leadership position within the growing
diabetes market
Novo NordiskⓇ
Global diabetes market by treatment class¹
Novo Nordisk remains global diabetes value
market leader
Novo Nordisk market share and share of
growth
DKK
billion
500
Market CAGR: 10%
60%
11%
13% 13%
14%
14% 14%
400
21%
21% 21%
23% 24%
25%
40%
33%
40%
300
CAGR: -3%
CAGR: 33%
38%
36% 35%
30% 29% 28%
200
CAGR: -4%
20%
32%
25%
100
30%
31%
31%
32% 33% 33%
CAGR: 29%
0
2018
2019
2020
2021
2022
H1
2021
0%
H2 H1 H2 H1 Q3
2021 2022 2022 2023 2023
Aug
Aug
2020
2023
GLP-1
Insulin
SGLT-2i
DPP-4i
Company A
Company B
Others
Novo Nordisk
NN market share
-NN share of growth
-Market growth (right axis)
NN growth (right axis)
1 Data is based on company reported sales. Data does not include generic metformin, sulphonylureas or thiazolidinedione
NN: Novo Nordisk
Source: IQVIA MAT, Aug 2023 value figures Note: IQVIA data can be inflated due to use of list prices. Due to contractual obligations competitor names are not disclosed. Company A and B represent actual companiesView entire presentation